trending Market Intelligence /marketintelligence/en/news-insights/trending/CbyhP9Ba6iO4H6k0we2mbQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

ArcherDX, Illumina to team up to co-market cancer diagnostic tests

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


ArcherDX, Illumina to team up to co-market cancer diagnostic tests

ArcherDX Inc. signed a nonexclusive multiyear agreement with San Diego-based Illumina Inc. to co-market a portfolio of planned in vitro diagnostic test kits to detect cancer.

Boulder, Colo.-based ArcherDX is a private molecular technology company that develops solutions to advance the application of personalized genomic medicine.

Under the agreement, the companies will co-promote future ArcherDX's in vitro diagnostic, or IVD, tests that use Illumina's NextSeq 550Dx and MiSeq Dx systems. The tests will generate genomic information to determine optimal cancer treatment and provide clinicians and patients with information for cancer monitoring and recurrence surveillance.

Illumina's sequencing instruments, combined with ArcherDX's IVD kits and its software, will allow these platforms to guide clinical decision-making and targeted therapy, said ArcherDX CEO Jason Myers.

ArcherDX expects its Stratafide companion diagnostic to be the first IVD test to receive U.S. Food and Drug Administration approval under the partnership. The company plans to seek regulatory approval for its Personalized Cancer Monitoring product later.

Stratafide was granted the FDA's breakthrough device designation in early 2019.

ArcherDX and Illumina have previously worked together to develop, market and promote research products in markets outside the U.S.

Illumina signed a nonexclusive agreement Sept. 24, 2019, with Adaptive Biotechnologies Corp. to develop IVD test kits for cancer detection.